Analysis of fetal DNA in maternal blood non-invasive fetal diagnostic tests for blood group and sex determination

1. Some pregnant women have antibodies to (have become immunised against) the blood group of the fetus, which represents a risk to the fetus. The use of NIPD to determine the blood group of the fetus may help to improve the safety of medical care offered to these women and their unborn children.2. S...

Full description

Bibliographic Details
Main Authors: Sahlin, Nils-Eric, Wahlström, Jan (Author)
Corporate Author: Statens beredning för medicinsk utvärdering (Sweden)
Format: eBook
Language:English
Published: Stockholm SBU 2011, 2011
Series:SBU alert report
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02037nam a2200265 u 4500
001 EB002001189
003 EBX01000000000000001164090
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
100 1 |a Sahlin, Nils-Eric 
245 0 0 |a Analysis of fetal DNA in maternal blood  |h Elektronische Ressource  |b non-invasive fetal diagnostic tests for blood group and sex determination  |c co-authors, Nils-Eric Sahlin, Jan Wahlström 
260 |a Stockholm  |b SBU  |c 2011, 2011 
300 |a 1 PDF file (4 pages) 
505 0 |a Includes bibliographical references 
700 1 |a Wahlström, Jan  |e [author] 
710 2 |a Statens beredning för medicinsk utvärdering (Sweden) 
740 0 2 |a Analys av foster-DNA i kvinnans blod 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a SBU alert report 
500 |a Summary of Analys av foster-DNA i kvinnans blod. 2011 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK298985  |3 Volltext 
082 0 |a 610 
520 |a 1. Some pregnant women have antibodies to (have become immunised against) the blood group of the fetus, which represents a risk to the fetus. The use of NIPD to determine the blood group of the fetus may help to improve the safety of medical care offered to these women and their unborn children.2. Screening for fetal blood group using NIPD, in combination with specific prenatal preventive measures (targeted RhD prophylaxis), could result in fewer RhD-negative pregnant women developing antibodies to RhD. The organisational and health economic consequences of introducing this type of screening have not been established.3. The use of NIPD to determine fetal sex when this is medically justified could improve the safety of medical care by reducing the need for invasive fetal diagnostic tests. The technique is not currently used for this purpose in Sweden.4. There is a lack of published research into the cost-effectiveness of using NIPD to determine fetal sex or blood group